SERB acquires the rights to Xermelo® outside US and Japan for Carcinoid Syndrome Diarrhoea
April 04, 2022 02:08 ET
|
BTG Specialty Pharmaceuticals
Paris, April 04, 2022 (GLOBE NEWSWIRE) -- SERB is pleased to announce it has acquired the rights from Ipsen to commercialize Xermelo® (telotristat ethyl) in Europe and other countries outside the US...